These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 35436984)
1. B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36. Zhang H; Li Y; Zhang C; Huang K; Zhao J; Le S; Jiang L; Liu H; Yang P; Xiao X; Yu J; Wu J; Ye P; Xia J Cell Death Dis; 2022 Apr; 13(4):359. PubMed ID: 35436984 [TBL] [Abstract][Full Text] [Related]
2. Chemically synthesized osteocalcin alleviates NAFLD via the AMPK-FOXO1/BCL6-CD36 pathway. Zhang M; Dong K; Du Q; Xu J; Bai X; Chen L; Yang J J Transl Med; 2024 Aug; 22(1):782. PubMed ID: 39175012 [TBL] [Abstract][Full Text] [Related]
3. GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice. Lu Z; Li Y; Syn WK; Li AJ; Ritter WS; Wank SA; Lopes-Virella MF; Huang Y Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E30-E42. PubMed ID: 33103454 [TBL] [Abstract][Full Text] [Related]
4. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141 [TBL] [Abstract][Full Text] [Related]
5. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36. Zhu H; Zhao T; Zhao S; Yang S; Jiang K; Li S; Kang Y; Yang Z; Shen J; Shen S; Tao H; Xuan J; Yang M; Xu B; Wang F; Jiang M Metabolism; 2024 Jul; 156():155914. PubMed ID: 38642829 [TBL] [Abstract][Full Text] [Related]
6. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Zhang X; Li S; Zhou Y; Su W; Ruan X; Wang B; Zheng F; Warner M; Gustafsson JÅ; Guan Y Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3181-3185. PubMed ID: 28270609 [TBL] [Abstract][Full Text] [Related]
7. Prolactin improves hepatic steatosis via CD36 pathway. Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209 [TBL] [Abstract][Full Text] [Related]
8. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. Wilson CG; Tran JL; Erion DM; Vera NB; Febbraio M; Weiss EJ Endocrinology; 2016 Feb; 157(2):570-85. PubMed ID: 26650570 [TBL] [Abstract][Full Text] [Related]
9. Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice. Chikada H; Ida K; Nishikawa Y; Inagaki Y; Kamiya A Sci Rep; 2020 Jun; 10(1):9704. PubMed ID: 32546802 [TBL] [Abstract][Full Text] [Related]
10. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice. Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834 [TBL] [Abstract][Full Text] [Related]
11. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice. Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245 [TBL] [Abstract][Full Text] [Related]
12. Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the expression of the fatty acid transporter CD36. Shen C; Chen JH; Oh HR; Park JH FEBS Lett; 2021 Oct; 595(19):2493-2503. PubMed ID: 34536973 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast. Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603 [TBL] [Abstract][Full Text] [Related]
15. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice. Wang X; Ren Q; Wu T; Guo Y; Liang Y; Liu S Mol Med Rep; 2014 Dec; 10(6):2917-23. PubMed ID: 25310357 [TBL] [Abstract][Full Text] [Related]
16. Loss of GPR40 in LDL receptor-deficient mice exacerbates high-fat diet-induced hyperlipidemia and nonalcoholic steatohepatitis. Lu Z; Li Y; Li AJ; Syn WK; Wank SA; Lopes-Virella MF; Huang Y PLoS One; 2022; 17(11):e0277251. PubMed ID: 36331958 [TBL] [Abstract][Full Text] [Related]
17. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease. Liu X; Chen S; Zhang L Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319 [TBL] [Abstract][Full Text] [Related]
18. Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance. Steneberg P; Sykaras AG; Backlund F; Straseviciene J; Söderström I; Edlund H J Biol Chem; 2015 Jul; 290(31):19034-43. PubMed ID: 26085100 [TBL] [Abstract][Full Text] [Related]
19. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823 [TBL] [Abstract][Full Text] [Related]
20. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing. Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]